Bain Capital Life Sciences Investors as of June 30, 2025
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 23 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 24.3 | $194M | 11M | 18.11 | |
| Cidara Therapeutics Com New (CDTX) | 15.2 | $122M | 2.5M | 48.71 | |
| Nuvalent Inc-a (NUVL) | 13.8 | $110M | 1.4M | 76.30 | |
| Pharvaris N V (PHVS) | 7.3 | $58M | 3.3M | 17.60 | |
| Dianthus Therapeutics (DNTH) | 5.8 | $46M | 2.5M | 18.63 | |
| Savara (SVRA) | 5.0 | $40M | 18M | 2.28 | |
| Solid Biosciences Com New (SLDB) | 4.8 | $39M | 7.9M | 4.87 | |
| Disc Medicine (IRON) | 3.9 | $31M | 584k | 52.96 | |
| Olema Pharmaceuticals (OLMA) | 3.6 | $29M | 6.8M | 4.26 | |
| Rapid Micro Biosystems Class A Com (RPID) | 3.6 | $29M | 8.4M | 3.45 | |
| Upstream Bio (UPB) | 3.4 | $27M | 2.4M | 10.98 | |
| Cabaletta Bio (CABA) | 1.8 | $15M | 9.7M | 1.52 | |
| Tango Therapeutics (TNGX) | 1.7 | $14M | 2.7M | 5.12 | |
| Annexon (ANNX) | 1.6 | $13M | 5.2M | 2.40 | |
| Kyverna Therapeutics (KYTX) | 1.3 | $10M | 3.4M | 3.07 | |
| Atea Pharmaceuticals (AVIR) | 1.1 | $8.9M | 2.5M | 3.60 | |
| Xilio Therapeutics (XLO) | 0.4 | $3.1M | 4.6M | 0.68 | |
| Century Therapeutics (IPSC) | 0.4 | $3.0M | 5.4M | 0.56 | |
| Mersana Therapeutics | 0.3 | $2.6M | 8.7M | 0.30 | |
| C4 Therapeutics Com Stk (CCCC) | 0.2 | $1.6M | 1.1M | 1.43 | |
| Adagio Therapeutics (IVVD) | 0.2 | $1.3M | 1.8M | 0.71 | |
| X4 Pharmaceuticals Com New (XFOR) | 0.1 | $1.1M | 564k | 1.90 | |
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.1 | $800k | 100k | 8.00 |
